Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study

Published:2024-09 Issue:9 Volume:9 Page:103697
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Rugo H.S.,Oliveira M.,Howell S.J.,Dalenc F.,Cortes J.,Gomez H.L.,Hu X.,Jhaveri K.L.,Krivorotko P.,Loibl S.,Morales Murillo S.,Nowecki Z.,Okera M.,Park Y.H.,Sohn J.,Toi M.,Iwata H.,Yousef S.,Zhukova L.,Logan J.,Twomey K.,Khatun M.,D’Cruz C.M.,Turner N.C.

Funder

AstraZeneca PLC

Publisher

Elsevier BV

Reference18 articles.

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer (Version 2.2024);© National Comprehensive Cancer Network, Inc,2024

2. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer;Gennari;Ann Oncol,2021

3. CDK4/6 inhibitor resistance mechanisms and treatment strategies (review);Huang;Int J Mol Med,2022

4. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors;Millis;JAMA Oncol,2016

5. Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications;Toss;Oncotarget,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP